Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search
  1. NCI-F Publications

Search
  1. Year Published:

Your search returned 44 results.
User Information
Export Records
  1. 1.   Complex Tumor Spheroids, a Tissue-Mimicking Tumor Model, for Drug Discovery and Precision Medicine
  2. Kaur, Gurmeet; Evans, David M.; Teicher, Beverly A.; Coussens,Nathan
  3. SLAS Discovery. 2021, Nov 12;
  1. 2.   Specific RITA modification produces hyperselective cytotoxicity while maintaining in vivo antitumor efficacy
  2. Peyser,Brian; Hermone,Ann; Salamoun, Joseph M; Burnett, James C; Hollingshead,Melinda; McGrath,Connor; Gussio,Rick; Wipf, Peter
  3. Molecular cancer therapeutics. 2019, OCT; 18(10): 1765-1774.
  1. 3.   Overexpression of IL-38 protein in anticancer drug-induced lung injury and acute exacerbation of idiopathic pulmonary fibrosis
  2. Tominaga, Masaki; Okamoto, Masaki; Kawayama, Tomotaka; Matsuoka, Masanobu; Kaieda, Shinjiro; Sakazaki, Yuki; Kinoshita, Takashi; Mori, Daisuke; Inoue, Akira; Hoshino, Tomoaki
  3. Respiratory Investigation. 2017, Sep; 55(5): 293-299.
  1. 4.   Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-p-activated nitric oxide donor PABA/NO in malignant gliomas
  2. Kogias, E.; Osterberg, N.; Baumer, B.; Psarras, N.; Koentges, C.; Papazoglou, A.; Saavedra, J. E.; Keefer, L. K.; Weyerbrock, A.
  3. International Journal of Cancer. 2012, Mar; 130(5): 1184-1194.
  1. 5.   CEBPD Reverses RB/E2F1-Mediated Gene Repression and Participates in HMDB-Induced Apoptosis of Cancer Cells
  2. Pan, Y. C.; Li, C. F.; Ko, C. Y.; Pan, M. H.; Chen, P. J.; Tseng, J. T.; Wu, W. C.; Chang, W. C.; Huang, A. M.; Sterneck, E.; Wang, J. M.
  3. Clinical Cancer Research. 2010, Dec; 16(23): 5770-5780.
  1. 6.   Elucidation of the Molecular Mechanisms of a Salicylhydrazide Class of Compounds by Proteomic Analysis
  2. Cao, X. F.; Plasencia, C.; Kanzaki, A.; Yang, A.; Burke, T. R.; Neamati, N.
  3. Current Cancer Drug Targets. 2009 9(2): 189-201.
  1. 7.   Botryllamides: Natural Product Inhibitors of ABCG2
  2. Henrich, C. J.; Robey, R. W.; Takada, K.; Bokesch, H. R.; Bates, S. E.; Shukla, S.; Ambudkar, S. V.; McMahon, J. B.; Gustafson, K. R.
  3. Acs Chemical Biology. 2009 4(8): 637-647.
  1. 8.   DNA fingerprinting of the NCI-60 cell line panel
  2. Lorenzi, P. L.; Reinhold, W. C.; Varma, S.; Hutchinson, A. A.; Pommier, Y.; Chanock, S. J.; Weinstein, J. N.
  3. Molecular Cancer Therapeutics. 2009 8(4): 713-724.
  1. 9.   Expression of 25 human ABC transporters in the yeast Pichia pastoris and characterization of the purified ABCC3 ATPase activity
  2. Chloupkova, M.; Pickert, A.; Lee, J. Y.; Souza, S.; Trinh, Y. T.; Connelly, S. M.; Dumont, M. E.; Dean, M.; Urbatsch, I. L.
  3. Biochemistry. 2007, Jul; 46(27): 7992-8003.
  1. 10.   Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study
  2. Shankavaram, U. T.; Reinhold, W. C.; Nishizuka, S.; Major, S.; Morita, D.; Chary, K. K.; Reimers, M. A.; Scherf, U.; Kahn, A.; Dolginow, D.; Cossman, J.; Kaldjian, E. P.; Scudiero, D. A.; Petricoin, E.; Liotta, L.; Lee, J. K.; Weinstein, J. N.
  3. Molecular Cancer Therapeutics. 2007, Mar; 6(3): 820-832.
  1. 11.   Crinamine from Crinum asiaticum var.japonicum inhibits hypoxia inducible factor-1 activity but not activity of hypoxia inducible factor-2
  2. Kim, Y. H.; Park, E. J.; Park, M. H.; Badarch, U.; Woldemichael, G. M.; Beutler, J. A.
  3. Biological & Pharmaceutical Bulletin. 2006, Oct; 29(10): 2140-2142.
  1. 12.   Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt
  2. Gills, J. J.; Holbeck, S.; Hollingshead, M.; Hewitt, S. M.; Kozikowski, A. P.; Dennis, P. A.
  3. Molecular Cancer Therapeutics. 2006, Mar; 5(3): 713-722.
  1. 13.   Novel human monoclonal antibodies to insulin-like growth factor (IGH)-II that potently inhibit the IGF receptor type I signal transduction function
  2. Feng, Y.; Zhu, Z. Y.; Xiao, X. D.; Choudhry, V.; Barrett, J. C.; Dimitrov, D. S.
  3. Molecular Cancer Therapeutics. 2006, JAN; 5(1): 114-120.
  1. 14.   Drugs aimed at targeting characteristic karyotypic phenotypes of cancer cells
  2. Wallqvist, A.; Huang, R.; Covell, D. G.; Roschke, A. V.; Gelhaus, K. S.; Kirsch, I. R.
  3. Molecular Cancer Therapeutics. 2005, OCT; 4(10): 1559-1568.
  1. 15.   Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics
  2. Sun, H. Y.; Nikolovska-Coleska, Z.; Chen, J. Y.; Yang, C. Y.; Tomita, Y.; Pan, H. G.; Yoshioka, Y.; Krajewski, K.; Roller, P. P.; Wang, S. M.
  3. Bioorganic & Medicinal Chemistry Letters. 2005, FEB 1; 15(3): 793-797.
  1. 16.   Cytotoxicity of RH1: NAD(P)H : quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction
  2. Tudor, G.; Alley, M.; Nelson, C. M.; Huang, R. L.; Covell, D. G.; Gutierrez, P.; Sausville, E. A.
  3. Anti-Cancer Drugs. 2005 16(4): 381-391.
  1. 17.   Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action
  2. Huang, R.; Wallqvist, A.; Thanki, N.; Covell, D. G.
  3. Pharmacogenomics Journal. 2005 5(6): 381-399.
  1. 18.   Anticancer metal compounds in NCI's tumor-screening database: putative mode of action
  2. Huang, R. L.; Wallqvist, A.; Covell, D. G.
  3. Biochemical Pharmacology. 2005 69(7): 1009-1039.
  1. 19.   Fluorinated 2-(4-amino-3-methylphenyl) benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells
  2. Brantley, E.; Trapani, V.; Alley, M. C.; Hose, C. D.; Bradshaw, T. D.; Stevens, M. F. G.; Sausville, E. A.; Stinson, S. F.
  3. Drug Metabolism and Disposition. 2004, DEC; 32(12): 1392-1401.
  1. 20.   Components of the cell death machine and drug sensitivity of the National Cancer Institute cell line panel
  2. Svingen, P. A.; Loegering, D.; Rodriquez, J.; Meng, X. W.; Mesner, P. W.; Holbeck, S.; Monks, A.; Krajewski, S.; Scudiero, D. A.; Sausville, E. A.; Reed, J. C.; Lazebnik, Y. A.; Kaufmann, S. H.
  3. Clinical Cancer Research. 2004, OCT 15; 10(20): 6807-6820.
  1. 22.   Small molecule toxins targeting tumor receptors
  2. Dyba, M.; Tarasova, N. I.; Michejda, C. J.
  3. Current Pharmaceutical Design. 2004 10(19): 2311-2334.
  1. 23.   The hollow fibre model in cancer drug screening: the NCI experience
  2. Decker, S.; Hollingshead, M.; Bonomi, C. A.; Carter, J. P.; Sausville, E. A.
  3. European Journal of Cancer. 2004 40(6): 821-826.
  1. 24.   Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XLAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database
  2. Nikolovska-Coleska, Z.; Xu, L.; Hu, Z. J.; Tomita, Y.; Li, P.; Roller, P. P.; Wang, R. X.; Fang, X. L.; Guo, R. B.; Zhang, M. C.; Lippman, M. E.; Yang, D. J.; Wang, S. M.
  3. Journal of Medicinal Chemistry. 2004 47(10): 2430-2440.
  1. 25.   Aryl hydrocarbon receptor activation of an antitumor aminoflavone: Basis of selective toxicity for MCF-7 breast tumor cells
  2. Loaiza-Perez, A. I.; Kenney, S.; Boswell, J.; Hollingshead, M.; Alley, M. C.; Hose, C.; Ciolino, H. P.; Yeh, G. C.; Trepel, J. B.; Vistica, D. T.; Sausville, E. A.
  3. Molecular Cancer Therapeutics. 2004 3(6): 715-725.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel